NEW YORK, Sept. 17 — EuroProteome announced today that it has secured €9.5 million in a financing round. The Hennigsdorf, Germany-based company, which calls itself a "human cancer proteomiucs company," is developing clinical tools for early diagnostics, prognostics, and patient-specific therapeutics and immune therapeutics for the treatment of epithelial cancers. The round was led by German VC firms Earlybird Venture Capital and Heidelberg Innovation. Nextech Venture and Aventic Partners, both of Zurich, also contributed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.